Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.

about

Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain.Anticoagulants, renal failure and atrial fibrillation.

P2860

Q38221812-56D844D5-BF1B-4A34-B281-47ED3C9246C9 Q39204242-67B9B884-9A6A-4A01-B3BE-B2BBE83F3562 Q45164954-F44D270F-1496-4603-B83E-49E776B5CD63

P2860

Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.

Item

http://www.wikidata.org/entity/Q38055261

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Anticoagulation in atrial fibr ...... sease: efficacy versus safety.

@en

type

Item

label

Anticoagulation in atrial fibr ...... sease: efficacy versus safety.

@en

prefLabel

Anticoagulation in atrial fibr ...... sease: efficacy versus safety.

@en

P1476

Anticoagulation in atrial fibr ...... isease: efficacy versus safety

@en

P2093

Imtiaz Salim

http://www.w3.org/2001/XMLSchema#string

Wissam Ghadban

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality

Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke

Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Validation of Clinical Classification Schemes for Predicting Stroke

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

P304

53-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2013.732569

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Amar M Salam

J Al Suwaidi

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23095103

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.

about

P2860

P2860

Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921